



12 June 2018

Results of Entitlement Offer Strong Validation for Company Plan and New Strategic Direction

CardieX Limited (ASX: ACG, CardieX, the Company) is pleased to announce the successful completion of the Company's Non-Renounceable Entitlement Offer (Offer), as announced on 23 April 2018.

The offer was heavily oversubscribed and a total of \$907,882 in Entitlement Acceptances will be returned to shareholders.

The Company confirms that a total of 56,204,699 shares under the Offer are to be issued on 14 June 2018. An Appendix 3B will be issued separately with the ASX on that day. The new shares are expected to commence normal trading from 15 June 2018, on the ASX.

This will lead to an increase in cash balances in the company of \$1,124,094 (pre-costs of the entitlement issue).

Due to the Offer being heavily oversubscribed, CardieX has committed to finding a fair and equitable solution to allocate the New Shares to the participants.

Upon careful consideration of the Prospectus as issued to shareholders, it was determined that Additional Shares would be issued utilising a pro rata approach to the participation of New Shares (as defined in the Prospectus). This is based on a ratio of entitlements of those participating out of the total entitlements issued.

The results of the pro rata allocation of Additional Shares will be rounded up, to ensure the maximum additional entitlement is the greater of either the 'over' as per the above ratio, or the amount of their original entitlement to New Shares.

The Company would like to thank all the participants in the Entitlement Offer, which has shown shareholders are confident in the future of the Company with its new direction of focus.

CardieX CEO Craig Cooper commented:

"The success of the Offer shows strong validation for the strategy and new direction of the Company as previously outlined to shareholders. I would like to thank all new and existing shareholders for their support as we continue to build a world class health technology company".

For personal use only

About CardieX

CardieX is a global health technology company focused on developing solutions for large-scale population health disorders. The Company's "AtCor Medical" division develops and markets products for the early detection of target organ damage and management of cardiovascular and renal disease.

For more information please contact:

Chief Executive Officer

Craig Cooper

Ph: +61 429 993 399

ccooper@cardiex.com

Investor Relations

Peter Taylor

Ph: +61 412 036 231

peter@nwrcommunications.com.au

Chief Financial Officer

Jarrold White

Ph: +61 2 8296 0000

jwhite@cardiex.com

For personal use only